A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies
Public ClinicalTrials.gov record NCT03310619. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Exploratory Phase 1/2 Trial To Evaluate The Safety And Efficacy Of JCAR017 Combinations In Subjects With Relapsed/Refractory B-Cell Malignancies (PLATFORM)
Study identification
- NCT ID
- NCT03310619
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Celgene
- Industry
- Enrollment
- 62 participants
Conditions and interventions
Interventions
- CC-122 Drug
- CC-220 Drug
- CC-99282 Drug
- Durvalumab Drug
- Ibrutinib Drug
- JCAR017 Biological
- Nivolumab Drug
- Relatlimab Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 19, 2017
- Primary completion
- Feb 14, 2023
- Completion
- Feb 14, 2023
- Last update posted
- Apr 3, 2024
2017 – 2023
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 011 | Duarte | California | 91010 | — |
| Local Institution - 022 | Atlanta | Georgia | 30342 | — |
| Local Institution - 014 | Chicago | Illinois | 60611-5975 | — |
| Local Institution - 012 | Boston | Massachusetts | 02114 | — |
| Local Institution - 021 | Boston | Massachusetts | 02215 | — |
| Local Institution - 015 | Omaha | Nebraska | 68198-7680 | — |
| Local Institution - 016 | Philadelphia | Pennsylvania | 19104 | — |
| Local Institution - 020 | Pittsburgh | Pennsylvania | 15232 | — |
| Local Institution - 013 | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03310619, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 3, 2024 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03310619 live on ClinicalTrials.gov.